What is mirror syndrome and what are the management options for a 36‑40‑week pregnant woman with a confirmed TORCH (Toxoplasmosis, Rubella, Cytomegalovirus, Herpes simplex virus) infection presenting with mirror syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirror Syndrome: Definition and Management at 36-40 Weeks with TORCH Infection

What is Mirror Syndrome?

Mirror syndrome (Ballantyne syndrome) is a serious maternal complication where the mother develops edema that "mirrors" her hydropic fetus, representing a form of severe preeclampsia caused by placental dysfunction and anti-angiogenic factor imbalance. 1

Clinical Features

The syndrome presents with a characteristic triad:

  • Maternal edema (occurs in approximately 90% of cases) 1
  • Hypertension (develops in 60% of cases) 1
  • Proteinuria (present in 40% of cases) 1

Additional maternal manifestations include:

  • Headache and visual disturbances 1
  • Oliguria and elevated uric acid 1
  • Elevated liver enzymes and creatinine 1
  • Thrombocytopenia, anemia, and hemodilution 1
  • Pulmonary edema (the major maternal morbidity, occurring in 21% of cases) 2

Pathophysiology

The hydropic placenta releases excessive anti-angiogenic factors (soluble fms-like tyrosine kinase-1 and soluble endoglin) into maternal circulation, triggering systemic endothelial dysfunction identical to severe preeclampsia. 3

Management at 36-40 Weeks with TORCH Infection

Immediate Delivery is Indicated

For most cases of non-immune hydrops fetalis (NIHF) without a treatable etiology, including TORCH infections at 36-40 weeks, development of mirror syndrome necessitates immediate delivery. 1

Delivery should not be delayed if the maternal condition deteriorates, even if this results in preterm birth. 1

Rationale for Delivery

  • At 36-40 weeks gestation, the fetus is at or near term, eliminating concerns about prematurity 1
  • TORCH infections (Toxoplasmosis, Rubella, Cytomegalovirus, Herpes) causing hydrops are not treatable in utero 1
  • Mirror syndrome resolves only with delivery or successful treatment of hydrops; since TORCH-related hydrops cannot be treated prenatally, delivery is the only definitive therapy 1
  • Expectant management risks severe maternal complications, particularly pulmonary edema 1, 2

Delivery Planning

Mode of delivery:

  • Consider cesarean delivery if the fetus is potentially viable and antepartum surveillance indicates fetal deterioration 4
  • Assess for large pleural or pericardial effusions that may complicate vaginal delivery 4

Delivery location:

  • All deliveries must occur at a tertiary center with Level III NICU capability to manage the critically ill hydropic neonate 1, 4
  • Transfer the mother before delivery if not already at an appropriate facility 4

Maternal Monitoring Prior to Delivery

If delivery is not immediately feasible, intensive maternal surveillance is required:

  • Serial blood pressure monitoring 1, 5
  • Assessment for signs of severe preeclampsia: right upper quadrant/epigastric pain, headache, visual disturbances 3
  • Laboratory monitoring: complete blood count (platelets), liver enzymes, renal function, uric acid 1, 3
  • Vigilance for pulmonary edema (the most serious complication) 1, 2

Critical Pitfalls to Avoid

  • Do not attempt expectant management at 36-40 weeks with mirror syndrome; the maternal risks outweigh any potential fetal benefit 1
  • Do not delay delivery hoping for spontaneous resolution; TORCH-related hydrops will not resolve in utero 1
  • Do not deliver at a facility lacking Level III NICU capabilities; this significantly worsens the already poor neonatal prognosis 1, 4

Prognosis

Maternal prognosis:

  • Mirror syndrome symptoms typically resolve 4.8-13.5 days after delivery 2
  • Full maternal recovery is expected with timely delivery 6

Fetal/neonatal prognosis:

  • Overall survival for NIHF is often <50% even without chromosomal abnormalities 1, 4
  • TORCH infections account for 5-10% of NIHF cases and carry guarded prognosis 1
  • Intrauterine death rate with mirror syndrome is approximately 56% 2

Evidence for Reversibility

The strongest evidence supporting delivery as definitive treatment comes from documented cases where successful treatment of treatable causes of hydrops (fetal arrhythmias, hydrothorax, parvovirus, bladder obstruction) led to resolution of both fetal hydrops and maternal mirror syndrome. 1, 3 However, TORCH infections do not fall into this treatable category, making delivery the only option for maternal recovery. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Guideline

Fetal Hydrops-Induced Maternal Pre-eclampsia Mechanism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Management of Non-Immune Hydrops Fetalis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Guideline

Management of Hydrops Fetalis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What proportion of patients with thalassemia trait have iron deficiency and what is the recommended treatment?
How should I manage a postpartum woman presenting with tachycardia, global left ventricular hypokinesia on echocardiography, a positive heart‑failure work‑up, and no evidence of an immune‑mediated cause?
Which antihistamine is preferred as an adjunct in anaphylaxis, and what are the recommended dose and route of administration for adults and children?
Which laboratory test is most useful to differentiate iron‑deficiency microcytic anemia from thalassemia trait?
How do I place a central venous catheter without ultrasound guidance, including indications, patient selection criteria, and the step‑by‑step landmark technique?
What oral antihypertensive medication should be started in an asymptomatic adult with a systolic blood pressure of 210 mm Hg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question